The efficacy of plasma rich in growth factors for the treatment of alveolar osteitis: A randomized controlled trial

King, E.M., Cerajewska, T.L., Locke, M., Claydon, Nicholas C.A. ORCID: https://orcid.org/0000-0002-4151-1515, Davies, M. and West, N.X. 2019. The efficacy of plasma rich in growth factors for the treatment of alveolar osteitis: A randomized controlled trial. Journal of Oral and Maxillofacial Surgery 76 (6) , pp. 1150-1159. 10.1016/j.joms.2017.12.025

Full text not available from this repository.

Abstract

Purpose To investigate the efficacy of plasma rich in growth factors (PRGF; BTI Biotechnology Institute, San Antonio, Spain) for the treatment of alveolar osteitis compared with a positive control (Alvogyl; Septodont, Maidstone, Kent, UK). Materials and Methods This single-center, single-blinded, randomized, 2-treatment, parallel study was conducted in a UK dental hospital. All healthy adults who presented with alveolar osteitis after tooth extraction over a 3-month period were invited to participate. Each socket was randomized and treated with 1 of 2 treatment modalities, a test treatment (PRGF) or a positive control (Alvogyl). After treatment, patients were reviewed at 3 and 7 days by a second clinician blinded to the treatment given. Outcome measures included pain, exposed bone, inflammation, halitosis, dysgeusia, and quality-of-life assessment. Results Thirty-eight patients with data from 44 sockets (22 in the PRGF group and 22 in the Alvogyl group) were analyzed. The PRGF group showed significantly faster bone coverage and significantly decreased inflammation and halitosis (P < .05) compared with the control group receiving Alvogyl. There was no significant difference for pain, quality-of-life measures, or dysgeusia between groups. Conclusion PRGF predictably treated alveolar osteitis after tooth extraction compared with the conventional standard treatment of Alvogyl, which has been used for many years. PRGF could be considered an alternative treatment for alveolar osteitis and indeed appears to have considerable advantages over Alvogyl.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Dentistry
Publisher:	WB Saunders
ISSN:	0278-2391
Date of Acceptance:	21 December 2017
Last Modified:	24 Oct 2022 08:32
URI:	https://orca.cardiff.ac.uk/id/eprint/118030

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item